DDInter1585 DDInter808
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Garlic allergenic extract is used in allergenic testing.
Reteplase {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfinpyrazone
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Bivalirudin
Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone
Reteplase may lead to a major life threatening interaction when taken with Edoxaban
Reteplase may lead to a major life threatening interaction when taken with Bivalirudin